Galapagos Valuation

Is G1LP34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of G1LP34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate G1LP34's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate G1LP34's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for G1LP34?

Key metric: As G1LP34 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for G1LP34. This is calculated by dividing G1LP34's market cap by their current revenue.
What is G1LP34's PS Ratio?
PS Ratio6.6x
Sales€260.09m
Market Cap€1.72b

Price to Sales Ratio vs Peers

How does G1LP34's PS Ratio compare to its peers?

The above table shows the PS ratio for G1LP34 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.7x
BLAU3 Blau Farmacêutica
1.6x11.7%R$2.6b
BIOM3 Biomm
9.4xn/aR$1.1b
HYPE3 Hypera
1.6x10.1%R$12.8b
DVAX Dynavax Technologies
6.3x17.6%US$1.6b
G1LP34 Galapagos
6.6x3.9%R$1.7b

Price-To-Sales vs Peers: G1LP34 is expensive based on its Price-To-Sales Ratio (6.6x) compared to the peer average (4.7x).


Price to Sales Ratio vs Industry

How does G1LP34's PS Ratio compare vs other companies in the Global Biotechs Industry?

277 CompaniesPrice / SalesEstimated GrowthMarket Cap
G1LP34 6.6xIndustry Avg. 9.0xNo. of Companies277PS01632486480+
277 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: G1LP34 is good value based on its Price-To-Sales Ratio (6.6x) compared to the Global Biotechs industry average (9x).


Price to Sales Ratio vs Fair Ratio

What is G1LP34's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

G1LP34 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.6x
Fair PS Ratio0.9x

Price-To-Sales vs Fair Ratio: G1LP34 is expensive based on its Price-To-Sales Ratio (6.6x) compared to the estimated Fair Price-To-Sales Ratio (0.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies